# GigaTIME (Valanarasu 2026 Cell) — 6-strategy bundle 한방 정리

**Date:** 2026-05-04 · **Owner:** Seungho Cook
**Commit:** `df54927` · **Files:** 6 / **Lines:** 700
**Reference:** Valanarasu JMJ et al., *Multimodal AI generates virtual population for tumor microenvironment modeling*, **Cell** 189(2):386–400.e19, Jan 2026, **DOI** 10.1016/j.cell.2025.11.016, **PMID** 41371214, CC-BY.
**Single-file shareable summary** for VS Code (Ctrl+Shift+V preview).

---

## 0. 한 줄 요약

> GigaTIME = Microsoft Research / Providence Health의 H&E → virtual mIF translator (40M paired cells, 14,256 patients, 24 cancers). 우리 H&E negative result (closure battery)는 **다른 task class** (continuous transcriptional regression vs image translation)에서 **다른 scale** (3.2K tiles vs 40M cells)이라 **complementary, not competing**. Marathon-safe 6 strategies (분석 X, citation/scaffolding only) commit `df54927`로 일괄 정리. **voice-protected sections (Hook/Aim/Disc 3.1/Lim/Cover Para 1/Q9) 무위반.**

---

## 1. 6 strategies — at a glance

| # | strategy | file | lines | who needs it |
|---|---|---|---|---|
| **S1** | Methods supp comparison table | `paper2a_gigatime_methods_comparison_table.md` | 67 | author → `07_star_methods.md` drop-in |
| **S2** | Reviewer Q1-Q8 GigaTIME scaffold | `paper2a_reviewer_q_gigatime_scaffold.md` | 94 | author → `09_reviewer_qa.md` (Q9 voice-protected 제외) |
| **S3** | THCA relevance scan | `gigatime_thca_relevance_scan.md` | 85 | foundation source for S1/S2/S4/S5/S6 |
| **S4** | Re-entry protocol v0 | `paper2a_reentry_protocol_v0.md` | 209 | Yu advisor briefing + grant + future-work |
| **S5** | Cover letter Para 2-3 scaffold | `paper1_cover_letter_para23_scaffold.md` | 130 | author → `08_cover_letter.md` (Para 1 voice-protected 제외) |
| **S6** | Venue justification memo | `paper1_venue_justification_gigatime.md` | 115 | Yu advisor input + venue ladder decision |

---

## 2. 핵심 framing (모든 6 doc 일관 — 이게 전부)

### A. Orthogonal complementarity (NOT competition)

| | GigaTIME | 우리 (Paper 2A) |
|---|---|---|
| **Task class** | image-to-image (H&E → virtual mIF) | continuous transcriptional regression (H&E → DM1_resid score) |
| **Output modality** | multi-channel protein image per cell | scalar molecular axis per spot |
| **Training paired data** | 40 × 10⁶ cells, H&E ↔ mIF | None for predictor (frozen ImageNet); ground-truth from 16 ST slides |
| **Cohort scale** | 14,256 patients × 51 hospitals × 24 cancers | 16 thyroid Visium slides × 3,200 tiles |
| **Result** | 1,234 protein-biomarker-staging-survival associations | r = 0.022, AUROC = 0.511 (chance) |
| **Pre-registered gate met** | not applicable (different task) | NO (gate +0.30 / +0.70) |

→ "Different task at different scale" — 우리 negative는 GigaTIME의 weakness가 아니라 **scope distinction**.

### B. THCA inclusion = HONEST UNKNOWN (S3 §2)

- 24 cancer types **not enumerated** in public metadata
- 21 protein panel **not enumerated**
- Microsoft Research + Providence Health 공개 자료 기준 — THCA 포함 여부 unconfirmed
- **우리 framing**: "GigaTIME provides general-cancer multimodal AI baseline; THCA-specific transcriptional axis is not addressed in their reported associations"
- ❌ 절대 안 함: "GigaTIME does X for THCA, we do Y for THCA" (unsupported)

### C. Re-entry conditions (5/5 모두 충족 시만)

| # | condition | 현재 | 정량 spec (S4) |
|---|---|---|---|
| 1 | Full-resolution scanner WSI ≥ 1 thyroid cohort | ❌ | 0.25-0.5 µm/pixel, ≥100 patients |
| 2 | Paired molecular labels (RNA + 8-gene) | ❌ | 100% pairing, ≥1 independent cohort |
| 3 | Post-marathon explicit decision | ❌ (5/4-6/13 marathon) | Paper 1 bioRxiv submit 후 |
| 4 | Foundation model access acquired + validated | ❌ | UNI/CONCH/Virchow2 + non-thyroid benchmark |
| 5 | Pre-registered hypothesis | ❌ | OSF/GitHub release before run |

**Total to meet**: 12-18 months + $30k-$70k + Bundang FFPE + Yu green light + grant funding.

### D. Forbidden language (변함없음)

- ❌ "GigaTIME-style multimodal AI 적용해서 image-DM1 success" (image-DM1 D 폐기 + 5 conditions 미충족)
- ❌ "Cancer Cell-ready" / "Nat Cancer reach" / venue-probability percentages
- ❌ "TROP2 spatially colocalizes with DM1-high spots" (Q3 NEG)
- ❌ "H&E-inferable molecular subtype" / "tile-level DM1 inference"
- ❌ "all risks resolved" / "모든 risk 해소"
- ❌ "proves" / "establishes" (use `supports` / `consistent with`)

---

## 3. S1 — Methods supp comparison table (drop-in markdown)

13-row side-by-side table for `07_star_methods.md`. Author copies. ~360 words. All cells source-traced.

**Key columns**: Task class · Output modality · Model class · Training paired data · Test cohort · Cancer scope · Image modality · Validation strategy · Negative controls · Primary metric · Result · Pre-registered gate · Scope of inference

**Closing 2 sentences**: "The two studies are therefore complementary rather than competing... Bridging the two — RNA-paired H&E training on a thyroid cohort at scale — is identified as the principal future-work direction."

---

## 4. S2 — Reviewer Q1-Q8 scaffold (Q9 voice-protected)

| Q | probability | topic | scaffold key point |
|---|---|---|---|
| **Q1** | high | "Why not UNI/CONCH/Virchow2 foundation model?" | gated, gain +0.05-0.15 < +0.28 GO gap; condition #4 future |
| **Q2** | high | "Why not GigaTIME?" | different task class (regression vs translation), different scale (3.2K vs 40M), our axis IS the molecular target GigaTIME would need |
| **Q3** | high | "Was hires Visium resolution sufficient?" | tissue_hires_scalef = 0.56, ~110 µm/tile = architecture only, not nuclear; condition #1 future |
| **Q4** | medium | "Slide-level aggregation rescue?" | top25_mean Spearman = 0.209 at n=16 (marginal, exploratory); reported but not used to flip verdict |
| **Q5** | medium | "Other tile sizes?" | 448 px Spearman = 0.017 (worse than 224); pre-registered +0.05 gate not met → 672 cancelled |
| **Q6** | medium | "Why does 9-dim RGB beat 2,048-dim ResNet50 on raw?" | raw signal is stain↔depth color artifact (DM1_raw ~ log_counts ρ = -0.45); residualization correctly removes confound |
| **Q7** | low | "Use GigaTIME's released model directly?" | model weights not located publicly (GitHub microsoft/GigaTIME 404; HuggingFace search empty); MS typically releases 6-12 mo post-pub |
| **Q8** | low | "ATC AUROC 0.689 contradict negative?" | gross anaplastic morphology distinguishable; consistent with H&E captures gross histology but not within-tumor molecular gradients |
| **Q9** | — | voice-protected | author keyboard, uses voice_hook_fact_brief §C dark-matter content |

---

## 5. S3 — GigaTIME THCA scan summary

### Confirmed (safe to cite)

- Cell 189(2):386–400.e19, Jan 2026, CC-BY, FWCI 10.47
- 21 authors (MS Research + Providence Cancer Institute + Providence Research Network)
- 14,256 patients × 51 hospitals × 7 US states × 24 cancers × 306 subtypes
- 40 × 10⁶ paired H&E ↔ mIF cells (21 proteins, panel NOT enumerated)
- 299,376 virtual mIF datasets generated
- 10,200 TCGA independent validation
- 1,234 protein-biomarker-staging-survival associations

### NOT confirmed (do NOT claim)

- THCA inclusion in 24 cancers — UNKNOWN (likely candidates not enumerated)
- 21 protein panel composition — UNKNOWN (likely standard immune mIF: CD3/4/8/20/68/163, FoxP3, HLA-DR, PD-1/L1, etc.)
- Specific AUC/accuracy benchmarks vs ResNet50 — NOT located
- Code/model weights public release — NOT located (GitHub 404, HuggingFace empty as of 2026-05-04)
- Supplementary file URLs — paywall + Cloudflare; Europe PMC ingestion pending

### Future re-verification

When (if) Microsoft releases code/weights (~6-12 months post-pub typical), check:
- `github.com/microsoft/GigaTIME` (currently 404)
- `huggingface.co/microsoft` (currently no GigaTIME-* model)

---

## 6. S4 — Re-entry protocol v0 (post-marathon planning)

### Phase architecture (post-conditions-met)

| phase | scope | wall time | compute cost |
|---|---|---|---|
| R0 | Pre-validation on non-thyroid benchmark (CAMELYON16/17 etc.) | 1 month | $1,000 |
| R1 | Foundation embedding on existing GSE250521 tiles | 1 week | $200 |
| R2 | Foundation embedding on full-res Bundang WSI (~100 patients) | 6 months | $5,000-$15,000 |
| R3 | RNA-paired multimodal training (GigaTIME-class mini) | 6 months | $20,000-$50,000 |
| R4 | External validation on TCGA-THCA WSI subset | 2 months | $1,000 |
| **TOTAL** | | **12-18 months** | **$30,000-$70,000** |

→ **Funded research program**, not marathon-mode side activity.

### Decision tree

```
Paper 1 bioRxiv (2026-06-13) submitted
  ↓
Funding secured (NIH R01 / Korean grant / industry)?
  ├── No → defer indefinitely, retain in Discussion future-work
  └── Yes → Bundang FFPE n ≥ 50?
        ├── No → outreach push + R0 with public benchmark
        └── Yes → Yu green light + pre-registration → R0-R4 sequential
```

### Reality check vs GigaTIME

- We don't need to match 14k patients
- Thyroid-specialized depth at 100-1k patients with high-quality paired RNA = "specialized vs general", not "competing"

---

## 7. S5 — Cover letter Para 2-3 scaffold

### Para 2 options (molecular-axis emphasis)

**Option 2A** — molecular axis emphasis (preferred): 8-gene RAI/DM1 transcriptional axis, driver-excluded design, DFI HR=1.41 multivariate, 4-step mechanism, TROP2 tumor-population vulnerability, honest spot-level NEG + functional validation acknowledgment

**Option 2B** — dark-matter emphasis: BRAF-neg ∩ RAS-neg n=156, DM1 vs DM2 cluster discrimination, N1 honest negative (HR=1.20 NS) pre-empts referee Q

### Para 3 options (positioning vs multimodal AI)

**Option 3A** — orthogonal complementarity (preferred): GigaTIME translates H&E → mIF at population scale; we establish 8-gene RNA transcriptional axis with pre-registered negative H&E feasibility; complementary, our axis = future H&E-paired training target

**Option 3B** — bridge-to-future: GigaTIME demonstrates feasibility at 10⁷ cells; our axis defines the molecular target; 5 conditions specify when image-DM1 angle could be re-opened

### Recommended sequencing
**2A → 3A** (molecular-first → image-AI-second, complementary framing)

### Para 1 = voice-protected (author keyboard)

---

## 8. S6 — Venue justification (for Yu advisor)

### Venue ladder re-assessment

| venue | probability | comment |
|---|---|---|
| Sci Rep / Endocrine-Related Cancer / Thyroid | high | base submission ready |
| **JCI Insight** | medium-high | **best calibrated reach** (mechanistic + translational + honest negative) |
| **Cell Rep Med** | medium-high | alternative reach |
| Cancer Discov | low-medium | needs +1-2 cohorts OR functional layer |
| Nat Cancer | low | needs pan-cancer OR multimodal AI bridge OR significant wet-lab |
| Cell | very low | not feasible without years more work |

### Honest reading

- **Default submit lane**: JCI Insight or Cell Rep Med primary reach; Sci Rep base
- GigaTIME publication does NOT directly elevate our submission lane (different lane), but establishes:
  - thyroid molecular axis space is editorially current
  - reviewers will ask about multimodal AI → S2 Q1/Q2 scaffolds pre-empt

### Yu input requested on

1. Cancer Discov first attempt? (low prob, high reward)
2. JCI Insight vs Cell Rep Med (which fits our package better)?
3. Cite GigaTIME in cover letter Para 3 (Option 3A) OR save for Discussion only?
4. Closure battery as Paper 1 Methods supp OR standalone Paper 2A?

---

## 9. Bib entry (commit `2ffe929`, `03_intro_references.bib`)

```bibtex
@article{Valanarasu2026,
  author    = {Valanarasu, ..., Poon, Hoifung},   % 21 authors
  title     = {{Multimodal AI generates virtual population for tumor microenvironment modeling}},
  journal   = {Cell},
  year      = {2026},
  volume    = {189},
  number    = {2},
  doi       = {10.1016/j.cell.2025.11.016}
}
```

(Full author list in actual bib file; cite as `\citep{Valanarasu2026}`.)

---

## 10. 모든 commit 한눈에 (오늘 + 이번 GigaTIME 통합)

| # | hash | 메시지 | 의미 |
|---|---|---|---|
| **last** | **`df54927`** | docs: gigatime leverage 6-strategy bundle | **이번 commit** (6 docs, 700 lines) |
| | `cf14656` | docs: draft paper1 STAR Methods supp entry for H&E negative feasibility | base supp draft |
| | `2ffe929` | docs: add Valanarasu 2026 Cell (GigaTIME) as multimodal-AI upper-bound cite | bib + supp + voice fact brief integrate |
| | `742d644` | docs: finalize marathon reentry status and runpod stop reminder | runpod_user_stop + classification |
| | `f66a6bb` | docs: lock paper1 molecular-only interpretation after dm1 full audit | molecular-only lock + conflict audit |
| | `1d16a4e` | decision: drop image-dm1 pathology angle after closure battery | image-DM1 angle 정식 폐기 |

---

## 11. 본인 다음 액션 (4가지)

| 액션 | Claude 도움 | 시간 |
|---|---|---|
| **Voice-protected 작성** (Hook ¶1 → Aim ¶4 → Disc 3.1 → Lim 3.4 → Cover Para 1 → Q9) | ❌ 본인 키보드 only | 본인 페이스 |
| **S1 (table) + S5 (Para 2-3) author 통합** — 6 doc → 실제 manuscript_v8 파일 copy/paste | ❌ author 책임 (voice 결정 필요) | ~30-60분 |
| **Yu advisor 미팅** — S6 venue memo + S4 re-entry protocol 들고 input 요청 | n/a | meeting time |
| **Pod C/D 즉시 stop** — runpod console에서 manual | ❌ Claude RunPod API 안 씀 | 5분 |

---

## 12. 추가 가능 옵션 (또 "고고" 시)

| 옵션 | 시간 | 산출물 |
|---|---|---|
| **A** Reviewer Q9-Q15 추가 scaffold (다른 axis: dark-matter, TROP2 spatial NEG, statistical power, single-cohort risk) | ~1시간 | 1 file |
| **B** Methods M1-M11 prose gap 보강 (이미 일부 있음, parallel agent와 충돌 주의) | ~1-2시간 | 1-2 file |
| **C** Figure caption GigaTIME-aware 보강 (`05_figure_captions.md`) | ~30분 | 1 patch |
| **D** Discussion §3 future-direction 1 sentence Claude scaffold (NOT §3.1 voice-protected) | ~20분 | 1 file |
| **E** Pre-registration template (S4 Phase R0 input, OSF style) | ~1시간 | 1 file |
| **F** STOP — voice-hook 본인 시작 | 0 | n/a |

---

## scp 명령 (Windows PowerShell)

```powershell
# 이 단일 요약 파일:
scp seungho@40.82.129.113:/home/seungho/personal/THCA_data_analysis/GIGATIME_BUNDLE_2026_05_04.md .

# 6개 strategy doc 한 번에:
scp -r seungho@40.82.129.113:/home/seungho/personal/THCA_data_analysis/project/reports/2026_05_04_*gigatime*.md .
scp seungho@40.82.129.113:/home/seungho/personal/THCA_data_analysis/project/reports/2026_05_04_paper2a_*.md .
scp seungho@40.82.129.113:/home/seungho/personal/THCA_data_analysis/project/reports/2026_05_04_paper1_cover_letter_para23_scaffold.md .
scp seungho@40.82.129.113:/home/seungho/personal/THCA_data_analysis/project/reports/2026_05_04_paper1_venue_justification_gigatime.md .

# 모든 reports (가장 단순):
scp -r seungho@40.82.129.113:/home/seungho/personal/THCA_data_analysis/project/reports .
```

VSCode:
```bash
code GIGATIME_BUNDLE_2026_05_04.md
# Ctrl+Shift+V → preview
```

---

## 13. 한 줄 next action

**Pod C/D stop (RunPod console) → S1+S5 author 통합 (manuscript_v8 copy/paste) → 본인 키보드 voice-hook ¶1 (`voice_hook_fact_brief.md` + 이 bundle 참조).** Claude는 prose 한 줄도 안 씀.

---

*Generated 2026-05-04 by Claude (Opus 4.7) under marathon-mode discipline. 6 strategies, 700 lines, single commit `df54927`. No analysis. No GPU. No RunPod. No prose modification of voice-protected sections (Hook/Aim/Discussion 3.1/Limitations 3.4/Cover Para 1/Reviewer Q9). All citations source-traced to S3 scan §1/§4 confirmed metadata only.*
